MEDDOCS
Open Access Publisher

ISSN: 2637-4900

Journal of Community Medicine

Open Access | Research Article

Evolution and Emergence of SARS-Covid-2 Vaccination and its Role in Prevention: Why the Race is Not for MERS?

***Corresponding Author(s): Kalpana Ramachandran**
Research Officer, Department of Epidemiology, The Tamil Nadu Dr. M.G.R. Medical University, Tamil Nadu, India.
Email: drkalpanaphd@gmail.com & depro1@tnmgrmu.ac.in

Received: Feb 15, 2021
Accepted: Mar 03, 2022
Published Online: Mar 07, 2022
Journal: Journal of Community Medicine
Publisher: MedDocs Publishers LLC
Online edition: http://meddocsonline.org/

Keywords: Covid-19; Vaccine efficacy; SARS-CoV-2.

Abstract

A novel coronavirus, currently known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), was identified as the source of a cluster of pneumonia cases in Wuhan, Hubei Province, China, near the end of 2019. It quickly spread over the world, resulting in a global epidemic. Vaccines against SARS-CoV-2 infection are seen to be the most promising method of containing the epidemic. Several vaccinations were available for use in various regions of the world by the end of 2020, with over 40 candidate vaccines in human studies and over 150 in preclinical trials. SARS-CoV-1 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) vaccine development set the ground for the quick development of COVID-19 vaccines. Many people with a history of SARS-CoV-2 infection may still benefit from vaccination. Vaccination appears to raise antibody levels and cell-mediated responses in people who have already been infected, perhaps improving the durability and breadth of protection. Vaccination has been linked to a decreased incidence of re-infection in observational studies of those who have once been infected. Vaccine efficacy may decline over time, according to various research. Myocarditis and pericarditis have been observed more frequently than predicted in male adolescents and young adults after receiving the mRNA vaccines BNT162b2 (Pfizer vaccine) and mRNA-1273. Vaccine efficacy against symptomatic disease remained high over six months, according to a follow-up analysis from phase III trial participants, but declined somewhat from 96 percent up to two months, 90 percent between two and four months, and 84 percent from four to six months. SARS-CoV-2 variants with immunological escape potential have been discovered all over the world. The effectiveness of the Delta vaccine against overall infection is diminished, although it is mostly conserved against severe sickness. According to preliminary findings, Omicron vaccination efficacy is reduced, notably against overall infection (B.1.1.529).

Cite this article: Ramachandran K. Evolution and Emergence of SARS-Covid-2 Vaccination and its Role in Prevention: Why the Race is Not for MERS?. J Community Med. 2022; 5(1): 1044.

Background

The past 20 years have seen a remarkable improvement in our knowledge of all elements of virology, fueled by new technologies such as genomics, proteomics, and molecular immunology, offering insights to lead new vaccine designs. Pathogenesis, serotype variety, antigenic variation, immune evasion mechanisms, latency, and route of transmission are all biological features of viruses that influence strategy selection of vaccine preparation [1]. For several of the viruses, new vaccine candidates have been reported, and while many are still in the early stages of development, some are well developed and have a realistic chance of being licenced within the next decade. Many infectious disease outbreaks have occurred in the recent two decades, including the Coronavirus Disease Pandemic of 2019 (COVID-19). COVID-19 began in China and has since extended to over 200 countries and territories. This virus is ravaging the world. Currently many vaccines are available and under experiment for covid-19. COVID-19 immunizations train our immune systems to recognise SARS-CoV-2, the virus that causes COVID-19, so that if we are infected, our immune systems can respond quickly and keep us well. Vaccines can protect us against COVID-19 by preventing us from becoming infected in the first place, as well as keeping us from becoming unwell, going to the hospital, or dying if we do become infected. Vaccines can also help to prevent the illness from spreading to others. COVID-19 vaccinations can prevent some or all of these health consequences, and clinical trial evidence aids our understanding of how vaccines keep us healthy [2]. Many phases are in vaccine trial, of which the major objective of most phase 3 clinical trials is Vaccine Effectiveness (VE) for symptomatic illness. If a COVID-19 vaccination's effectiveness against symptomatic disease is stated to be 95%, participants who got the vaccine were 95% less likely to suffer COVID-19 symptoms than those in the control group (the group that did not receive the vaccine). Vaccines may have various benefits in addition to the intended outcome. For example, numerous COVID-19 vaccine clinical trials indicated that the vaccination was 100 percent effective in avoiding severe disease, in addition to preventing symptomatic sickness. To put it another way, none of the vaccinated people were hospitalised or died from COVID-19, which is a fantastic result. After receiving the COVID-19 vaccine, we may have transitory symptoms similar to those experienced after receiving a flu shot, such as a sore, swollen arm where the shot was administered. For a day or two, you may have a fever, as well as body aches, headaches, and exhaustion. Swollen lymph nodes and chills are other possible side effects. These signs do not indicate that we are ill. They show that our immune system is reacting to the vaccine and strengthening its defences against the coronavirus [3]. Vaccination reduced transmission of SARS-CoV-2 from vaccinated patients who became ill before the introduction of the B.1.617.2 (delta) variety of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), possibly by lowering viral levels. Although vaccination still reduces the risk of infection, the fact that vaccinated and uninfected people with the delta variation have equal virus levels calls into question the extent to which vaccination prevents transmission. In this article, we try to review about the types of vaccine, approaches for vaccine preparation strategy, effectiveness, risk and its assessment and treatment practices for COVID vaccine.

Strategy for vaccine preparation

When producing a new vaccine, the method is decided on a case-by-case basis, with knowledge about the various factors of the pathogen like virus's pathogenicity, serotype variety, antigenic variation, immune evasion mechanisms, latency, and transmission route driving the decision [4]. The sort of immunity that develops as a result of natural infection, as well as whether the pathogen may cause persistent and/or recurring infections in a single host, are given a lot of weight. Before any vaccine candidate is confirmed to be both safe and effective, it is usually tested on a large number of people [5]. For example, around 7 out of every 100 vaccinations examined in the lab and on laboratory animals will be regarded good enough to advance into human clinical trials. Only one in every five vaccinations that make it to clinical trials is successful. Having a large number of vaccines in development raises the likelihood of one or more successful vaccines being demonstrated to be safe and effective for the prioritised populations [6]. Vaccines are thought to lower virus loads, hence limiting forward transmission.

Approach for vaccine preparation



Figure 1: There are three main approaches to making a vaccine.

Source: WHO

A vaccination can be designed in one of three ways (**Figure 3**). They differ in whether they use a whole virus or bacterium, simply the bits of the germ that trigger the immune system, or just the genetic information that supplies the instructions for manufacturing certain proteins rather than the entire virus (Figure 1) (Source: https://www.who.int/vaccines).

Types of vaccines

Type of vaccine	Licensed vaccines using this technology	First introduced
Live attenuated (weakened or inactivated)	Measles, mumps, rubella, yellow fever, influenza, oral polio, typhoid, Japanese encephalitis, rotavirus, BCG, varicella zoster	1798 (smallpox)
Killed whole organism	Whole-cell pertussis, polio, influenza, Japanese encephalitis, hepatitis A, rabies	1896 (typhoid)
Toxoid	Diphtheria, tetanus	1923 (diphtheria)
Subunit (purified protein, recombinant protein, polysaccharide, peptide)	Pertussis, influenza, hepatitis B, meningococcal, pneumococcal, typhoid, hepatitis A	1970 (anthrax)
Virus-like particle	Human papillomavirus	1986 (hepatitis B)
Outer membrane vesicle	Group B meningococcal	1987 (group B meningococcal)
Protein–polysaccharide conjugate	*Haemophilus influenzae* type B, pneumococcal, meningococcal, typhoid	1987 (*H. influenzae* type b)
Viral vectored	Ebola	2019 (Ebola)
Nucleic acid vaccine	SARS-CoV-2	2020 (SARS-CoV-2)
Bacterial vectored	Experimental	–
Antigen-presenting cell	Experimental	–

Figure 2: History of vaccine development.

Source: College of Physicians of Philadelphia. The History of Vaccines: Vaccine Development, Testing, and Regulation. https://www.historyofvaccines.org/content/articles/vaccine-development-testing-and-regulation.

When a novel virus appears that offers a serious threat to human health, such as the human coronavirus that caused Severe Acute Respiratory Syndrome (SARS) in 2002, work on developing a vaccine must begin immediately. In such a situation, time is a major obstacle. Developing a vaccine typically takes 8-12 years, from basic research to animal studies, clinical lot creation, analytical test development, clinical trials, industrial scale up, and licensure. In the event of an emergency, these timelines can be compressed, but this compression is limited. While current vaccine experience can be used, all processes and procedures must be examined, verified and applied.

There are numerous possible approaches to the development of a viral vaccine that can be usually described as follows: (Table 1).



Figure 3: Types of vaccine.

Table 1: Preparation of Vaccine.

Types of vaccine	Preparation
Live-attenuated vaccine	A live-attenuated vaccination employs a virus that is still alive but has been weakened, or one that is extremely similar. Ex: MMR
Inactivated vaccine	The first step in developing a vaccine is to inactivate or destroy the disease-carrying virus or bacteria, or one that is very similar to it, using chemicals, heat, or radiation. However, it necessitates specialised laboratory equipment to safely grow the virus or bacterium, can take a long time to produce, and will almost certainly require two or three doses to be administered.
The subunit approach	A subunit vaccination is one that only uses the bits of a virus or bacteria that the immune system needs to detect (the subunits). It doesn't employ a safe virus as a vector or contain the entire microorganism. Proteins or carbohydrates could be used as subunits. The majority of vaccinations on the paediatric immunisation schedule are subunit vaccines that protect against diseases like whooping cough, tetanus, diphtheria, and meningococcal meningitis.
The genetic approach (nucleic acid vaccine)	Unlike vaccines that use a full or parts of a weakened or dead microbe, a nucleic acid vaccine only uses a segment of genetic information that supplies the instructions for certain proteins, rather than the entire bacterium. Our cells employ DNA and RNA as instructions to produce proteins. DNA is converted to messenger RNA in our cells, which is then used as a blueprint to produce specific proteins.
Viral vector vaccine	This form of vaccine employs a safe virus to deliver specific sub-parts of the germ of interest, known as proteins, in order to elicit an immune response without causing disease. The instructions for producing specific portions of the pathogen of interest are introduced into a safe virus to accomplish this. After that, the virus acts as a platform or vector for delivering the protein into the body. The immunological response is triggered by the protein. The Ebola vaccine is a viral vector vaccine, which means it can be made quickly.
Vectored or chimeric virus approaches.	This occurs when a virus vaccination can be genetically engineered to carry genes expressing antigens from a different virus. The chimeric vaccine should retain the parent vaccination strain's attenuation and growth characteristics while also stimulating immunity to the foreign virus.

Why is there a rush or race for the Covid-19 vaccine?

Since the discovery of human coronaviruses in the 1960s, new forms of coronaviruses have emerged, posing a severe threat to public health around the world. Despite the fact that the first coronavirus outbreak occurred approximately two decades ago, the scientific and medical communities are still unprepared to tackle these viruses with effective weaponry. Given the pandemic's high fatality rate and rapid spread, an efficient vaccination is critical for its management. As a result, academia, industry, and government are collaborating in unprecedented ways to create and test a wide range of vaccinations. SARS-CoV-2 is highly contagious, having a reproductive number of 2.2, compared to SARS-CoV and MERS-CoV. Furthermore, its capacity to spread among asymptomatic individuals has made containment measures difficult to implement [7]. Many preclinical models have been used to generate and test vaccinations against SARS-CoV and MERS-CoV. However, only a few of these have gone through clinical testing, and none have been authorised by the FDA. Even if a safe and efficient SARS-CoV-2 vaccine is developed, the longevity of vaccine-induced protection remains uncertain. SARS-specific IgG and neutralising antibodies were only retained for around 2 years in patients who recovered from SARS-CoV infection, according to previous SARS research [8].

Table 2: List of approved Vaccines for Covid-19.

Name of the vaccine	Type of vaccine
Anhui Zhifei Longcom, ZF2001	Protein subunit
Bharat Biotech, Covaxin	Inactivated
Biological E Limited Corbevax	Protein subunit
CanSino, Convidecia	Non- replicating viral vector
Center for Genetic Engineering and Biotechnology (CIGB) Abdala	Protein subunit
Chumakov Center, KoviVac	Inactivated
FBRI, Aurora-CoV	Protein subunit
FBRI, EpiVacCorona	Protein subunit
Gamaleya, Sputnik Light	Non replicating viral vector
Gamaleya,Sputnik V	Non replicating viral vector
Health Institutes of Turkey, Turkovac	Inactivated
Instituto Finlay de Vacunas Cuba, Soberana 02	Protein subunit
Instituto Finlay de Vacunas Cuba, Soberana Plus	Protein subunit
Janssen (Johnson & Johnson),Ad26.COV2.S	Non-replicating viral vector
Kazakhstan RIBSP, QazVac	Inactivated
Medigen, MVC-COV1901	Pritein subunit
Minhai Biotechnology Co.KCONVAC	Inactivated
Moderna, Spikevax	RNA
National Vaccine and Serum Institute	Protein subunit
Recombinant SARS-CoV-2 Vaccine (CHO Cell)	
Novavax Nuvaxovid	Protein subunit
Organization of Defensive Innovation and Research	Inactivated
FAKHRAVAC (MIVAC)	
Oxford/AstraZeneca,Vaxzevria	Non replicating viral vector
Pfizer/BioNTech, Comirnaty	RNA
Razi Vaccine and Serum Research Institute	Protein subunit
Razi Cov Pars	
Serum Institute of India	Non replicating viral vector
Covishield (Oxford/ AstraZeneca formulation)	
Serum Institute of India	Protein subunit
COVOVAX (Novavax formulation)	
Shifa Pharmed Industrial Co,COVIran Barekat	Inactivated
Sinopharm (Beijing).Covilo	Inactivated
Sinopharm (Wuhan)-Inactivated (Vero Cells)	Inactivated
Sinovac CoronaVac	Inactivated
Takeda-TAK-919 (Moderna formulation)	RNA
Vaxine/CinnaGen Co.SpikoGen	Protein subunit
Zydus Cadila-ZyCoV-D	DNA

Source: https://covid19.trackvaccines.org/vaccines/approved/

Action of Covid-19 vaccination

Vaccines function by simulating an infectious agent, such as viruses, bacteria, or other microbes that might cause disease. This 'teaches' our immune system to respond quickly and efficiently to it. Vaccines have traditionally accomplished this by injecting a weakened form of an infectious pathogen into our bodies, allowing our immune systems to create a memory of it. Our immune system will be able to recognise it and battle it before it causes us to become ill. Some of the COVID-19 vaccines have been created in this manner. Other COVID-19 vaccines have been produced utilising novel methods known as messenger RNA vaccines, or mRNA vaccines. mRNA vaccines offer our bodies the genetic code they need to allow our immune systems to manufacture the antigen themselves, rather than introducing antigens (a material that prompts your immune system to produce antibodies). For decades, scientists have been researching mRNA vaccine technology. They don't contain any live viruses and aren't harmful to human DNA.

Common side effects of Covid-19 Vaccine

When any one has side effects after getting vaccinated, it shows that the vaccination is working and that your immune system is responding normally. Vaccines are safe, and getting one will assist you avoid contracting COVID-19. COVID-19 vaccines can cause side effects, mostly mild to moderate and have lasted no longer than a few days. Typical side effects include pain at the injection site, fever, fatigue, headache, muscle pain, chills and diarrhoea. Post-vaccination side effects for the first and second doses of Sinopharm COVID vaccination were mild and predictable, and there were no hospitalization cases; [9,10]. The chances of any of these side effects occurring after vaccination differ according to the specific vaccine. Less commonly, severe allergic reactions such as anaphylaxis can occur. We don't know how long COVID-19 vaccination protection lasts, but existing research suggests that most patients are protected for at least 6 months against major illness and death. Immunity may deteriorate more quickly in those who are older, have underlying medical issues, or have had a high amount of viral exposure. To protect our self, be vaccinated and continue to do the other COVID-19-protective behaviours. [11].

Risk assessment of Covid-19 Vaccination

Vaccine safety is a top priority for public health officials, policymakers, and the general public. Vaccinated people had a significantly reduced infection rate across the board. Over time, both vaccines showed an elevated incidence rate. Vaccination dramatically lowered the chance of death among people infected with COVID-19. The safety of the Astra Zeneca (AZ) COVID-19 vaccine (Vaxzevria) in relation to fatalities from rare, [12] atypical severe blood clots (Thrombosis and Thrombocytopenia Syndrome (TTS)) has fueled vaccination scepticism in several nations [13]. Despite the importance of vaccinations in pandemic management, Adverse Events Following Immunisation (AEFI), even if rare, have contributed to vaccine apprehension. Emerging AEFI reports have a lot of attention in the media even before there was proof of causation, affecting vaccine confidence and complicating risk-benefit assessments of mass immunisation programmes. Even rare cases of AEFI have resulted in modifications to national immunisation recommendations [14], a decision support tool for the ChAdOx1 nCov-19 vaccination in Australia that considers age, sex, local transmission, and other local characteristics, as recently published in Vaccine [15].

The COVID-19 Risk Calculator (CoRiCal) was created to fill a gap in the market for a user-friendly risk-benefit analysis tool to help doctors and the general public make informed COVID-19 vaccination decisions [16]. Bayesian Networks (BN) are conditional probability models that use directed acyclic graphs to express joint probabilities of occurrences. While calculating vaccine efficacy using, Bayesian network, here first we need to randomly assign study participants into two groups: vaccine

and placebo group. People in the first group, called the vaccine group, receive vaccines, and those in the placebo group receive placebo. The Vaccine Efficacy is estimated by the below formula,

Vaccine Efficacy = 100 x (1-IRR) (Incidence Rate Ratio)

IRR=Vaccine incidence rate/placebo incidence rate

Variables are visualised as nodes, with links between nodes expressing probabilistic parent-child relationships [17].



Figure 4: Bayesian networks model.

Nodes (boxes) and links (arrows) form probabilistic linkages (Figure 4) between parent and child nodes in Bayesian networks [18].

Risk calculators provide population-level estimates that can be used in public health, but professional counselling and decision-making for individuals should also take into account demographic and clinical data. Someone who has already experienced a possible vaccine-induced neurological problem after receiving the first dose of a vaccine is an extreme example; population-level risk-benefit calculations are estimates for the 'average person' and may not apply to this individual. CoRiCal and QCovid are two examples of calculators that could be integrated. Flexible modelling methodologies and risk-benefit visualisation tools could help promote evidence-based decision-making by providing global citizen access to the most up-to-date information, hence assisting global vaccination efforts [19].

COVID-19 vaccinations from Pfizer and Moderna are strongly recommended as safe and effective in preventing serious illness or death. The vaccines are safe and effective at preventing major disease or death due to COVID-19, according to data collected over the past 12 months, which includes data from tens of thousands of individuals in clinical trials. The bulk of these myocarditis instances occurred in teenagers and young adults, and the majority of them were moderate and went away on their own. According to a research published by the CDC, patients with COVID-19 had roughly 16 times the risk of myocarditis from March 2020 to January 2021 when compared to patients who did not have COVID-19 [20].

Risk of Oxford-Astra Zeneca ChAdOx1 nCoV-19 and Pfizer-BioNTech (BNT162b2 mRNA).

After receiving the initial doses of the both, ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines, there was an increase in the risk of haematological and vascular events that resulted in hospitalisation or death. In the same population, the risks of most of these events were significantly higher and lasted longer following SARS-CoV-2 infection [18]. A study reported, some nations have placed age-specific limits on the ChAdOx1 nCov-19 vaccination due to uncommon occurrences of thrombosis and Thrombocytopenia Syndrome (TTS), which are more common in younger age groups [21]. The BNT162b2 vaccination was not linked to an increased risk of the majority of the side effects studied. A higher risk of myocarditis was linked to the vaccination (1 to 5 events per 100,000 persons). After SARS-CoV-2 infection, the risk of this potentially serious adverse event, as well as many other serious adverse events, was significantly raised.

Even in the absence of prothrombotic risk factors, thrombotic problems arose after 2 weeks of exposure to vector-based SARS-CoV-2 vaccinations (mean interval 10 days; 95 percent CI 8-12) and primarily affected women (69 percent; 95 percent CI 60 percent-77 percent) under 45 [22].

According to a study by Palaiodimou et al., half of people who got TTS (Thrombocytopenia Syndrome) after receiving a vector-based vaccine (ChAdOx1 nCoV-19 or Ad26.COV2.S) developed CVST (Cerebral Venous Sinus Thrombosis), and TTS-associated CVST had a pooled death rate of 38%. When viewed in isolation, these figures are concerning and easily misinterpreted [23,24]. Hippisley-Cox et al. presented a large risk-benefit analysis of COVID-19 vaccinations focusing on thrombocytopenia and thrombosis [25]. Vaccinated individuals had a significant lower infection rate among all subgroups. An increased incidence rate was found in both vaccines over the time. Among individuals infected with COVID-19, vaccination significantly reduced the risk of death.



Figure 5: Risk of Various Covid-19 Vaccination.

On the basis of demographics and comorbidities, including neurological problems, models like QCovid predict the probability of death or hospitalisation from COVID-19. (Figure 5) ChAdOx1 nCov-19 Vaccine-Induced Thrombosis And Thrombocytopenia (VITT) typically manifests with, highly elevated serum IgG antibodies [26,27] to Platelet Factor 4 (PF4)-polyanion com-

plexes were found [28] often cerebral, venous thromboses, and also a few arterial thromboses were noted [29].

Efficacy rate of current Covid-19 vaccination

COVID vaccination breakthrough infections and associated risk factors are poorly understood. The COVID-19 vaccination protects against coronavirus infection, including its more severe variants. After a second dosage, the effectiveness of coronavirus immunisation begins to wane. Despite this, the vaccine's preventive effect against severe coronavirus disease lasts for at least six months in the majority of the population. Even if it doesn't entirely prevent illnesses, getting vaccinated helps to prevent the virus from spreading. The COVID-19 vaccine does not totally prevent the danger of infection and spread of the virus. As a result, even if you have been vaccinated, it is critical that you stay a safe distance from other people, wear a mask if necessary, wash your hands, and follow any other advice offered to prevent illnesses. Even if anyone have been vaccinated, a small number of people will become ill from COVID-19. There is currently minimal evidence about the danger of infected vaccinated people spreading the virus to others. Even after being fully vaccinated, it is critical to continue to exercise public health and social measures. The three US-approved COVID-19 vaccines have been shown to be highly effective against symptomatic COVID-19 infection in randomised clinical trials and observational studies. (30)Two types of vaccinations (an mRNA COVID-19 vaccine and the Janssen COVID-19 vaccine) were modelled; vaccine efficacy estimates were based on clinical trials 1-3, and efficacy was expected to develop 14 days after each dosage list in below Table 3.

Table 3: Efficacy of Covid-19 Vaccination.

Vaccine	Vaccine efficacy against infection	Vaccine efficacy against hospitalization or death
mRNA (First Dose)	70%	75%
mRNA (Both Doses)	85%	95%
J&J/Janssen	65%	90%

According to the health data.org, efficacy of different types of Covid-19 vaccine for various strains of Covid-19 are listed below in Table 4.

Table 4: Effectiveness of Covid-19 Vaccine against various strains.

		Ancestral		Alpha		Beta		Gamma		Delta		Omicron
Vaccine	Severe disease	Infection	Severe disease	Infection	Severe disease	Infection	Severe disease	Infection	Severe disease	Infection	Severe disease	Infection
AstraZeneca	94%	63%	94%	63%	94%	69%	94%	69%	94%	69%	71%	36%
CanSino	66%	62%	66%	62%	64%	61%	64%	61%	64%	61%	48%	32%
CoronaVac	50%	47%	50%	47%	49%	46%	49%	46%	49%	46%	37%	24%
Covaxin	78%	73%	78%	73%	76%	72%	76%	72%	76%	72%	57%	38%
Johnson & Johnson	86%	72%	86%	72%	76%	64%	76%	64%	76%	64%	57%	33%
Moderna	97%	92%	97%	92%	97%	91%	97%	91%	97%	91%	73%	48%
Novavax	89%	83%	89%	83%	86%	82%	86%	82%	86%	82%	65%	43%
Pfizer/BioNTech	95%	86%	95%	86%	95%	84%	95%	84%	95%	84%	72%	44%
Sinopharm	73%	68%	73%	68%	71%	67%	71%	67%	71%	67%	53%	35%
Sputnik-V	92%	86%	92%	86%	89%	85%	89%	85%	89%	85%	67%	44%
Other vaccines	75%	70%	75%	70%	73%	69%	73%	69%	73%	69%	55%	36%
Other vaccines	91%	86%	91%	86%	88%	85%	88%	85%	88%	85%	67%	45%

SARS-CoV-2 variants with immunological escape potential have been discovered all over the world. The effectiveness of the Delta vaccine against overall infection is diminished, although it is mostly conserved against severe sickness. According to preliminary findings, Omicron vaccination efficacy is reduced, notably against overall infection (B.1.1.529).

Management of contraindications to Covid-19 Vaccination

Rarely, anaphylaxis, a life-threatening allergic reaction, has been observed after COVID-19 vaccination [31]. At least 3 doses of age-appropriate epinephrine should be available at all times at COVID-19 immunisation sites, with the capacity to swiftly procure more doses to replenish supplies when epinephrine is provided to a patient. Locations giving COVID-19 vaccines to children under the age of 12 should have age-appropriate supplies, including epinephrine dosage. IV thrombolysis with alteplase and aspirin, followed by anticoagulation with an oral vitamin K antagonist, was started and resulted in a satisfactory outcome. Because of the rapid reduction in protein C, which could potentially aggravate thrombosis, vitamin K antagonist anticoagulation in the early stages of VITT with thrombocytopenia and disseminated intravascular coagulation is not indicated. Combined anticoagulation with aspirin 100 mg/d and subcutaneous danaparoid 2 × 750 mg/d on days 9-13, followed by phenprocoumon led to marked thrombus shrinkage and complete dissolution on day 28. [32].

Conclusion

One of the most effective methods to protect our families, communities, and ourselves from COVID-19 is to be vaccinated. Evidence suggests that immunizations are quite successful at avoiding COVID-19-related severe illness, hospitalisation, and mortality, including the Alpha and Delta versions of concern. However, because no vaccine has been demonstrated to be 100 percent effective against all outcomes for all age groups and variations, it's critical to continue to follow all public health standards and limit the risk of SARS-CoV-2 infection even after immunisation. While both mRNA vaccines were confirmed to be efficacious, we observed that Moderna/mRNA had a reduced rate of breakthrough infections. Over time, the incidence

rates of both vaccinations grew. SARS-CoV-2 variants with immunological escape potential have been discovered all over the world. The effectiveness of the Delta vaccine against overall infection is diminished, although it is mostly conserved against severe sickness. According to preliminary findings, Omicron vaccination efficacy is reduced, notably against overall infection (B.1.1.529). Data shows that the vaccines are quite effective at avoiding serious or fatal COVID-19 instances, even after a long period has passed since vaccination. Overall, the advantages of vaccination much outweigh the hazards involved.

References

1. Vaccines and Related Biological Products Advisory Committee. Vaccines and Related Biological Products Advisory Committee February 26, 2021, meeting FDA briefing document. Silver Spring, MD: U.S. Department of Health and Human Services, Food and Drug Administration. 2021.
2. James Hammitt's Faculty Website.
3. Johns Hopkins Medicine.
4. Wood DJ. New vaccine technologies. Dev Biol (Basel). 2002; 111: 285-290.
5. Kusters I, Almond JW. Vaccine Strategies. Encyclopedia of Virology. 2008: 235-243.
6. Buckland BC. The process development challenge for a new vaccine. Nature Medicine. 2005; 11: S16-S19.
7. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the Achilles Heel of current strategies to control covid-19. N Engl J Med. 2020; 382: 2158-2160.
8. Cao WC, Liu W, Zhang PH, Zhang F, Richardus JH. Disappearance of antibodies to SARS-associated coronavirus after recovery. N Engl J Med. 2007; 357: 1162-1163.
9. World Health Organization. Draft landscape of COVID-19 candidate vaccines. 2020.
10. Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021; 111: 219-226.
11. Balsam Qubais Saeed, Rula Al-Shahrabi, Shaikha Salah Alhaj, Zainab Mansour Alkokhardi, Ahmed Omar Adrees. Side effects and perceptions following Sinopharm COVID-19 vaccination, International Journal of Infectious Diseases. 2021; 111: 219-226.
12. Some common side affects you might experience after getting the COVID-19 vaccine.
13. Greinacher A, T Thiele, TE Warkentin, K Weisser, PA Kyrle, et al. "Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination." N Engl J Med. 2021.
14. Leask J, SJ Carlson, K Attwell, K Clark, J Kaufman, et al. "Communicating with patients and the public about COVID-19 vaccine safety: Recommendations from the Collaboration on Social Science and Immunisation." Med J Aust. 2021; 215: 9-12.e11.
15. Lau. Employed a Bayesian Network (BN) model to build CoRiCal (Covid Risk Calculator) Immunisation Coalition. CoRiCal: Covid Risk Calculator. 2021.
16. Lau CL, Helen J Mayfield, Jane E Sinclair, Samuel J Brown, Michael Waller, et al. Risk-benefit analysis of the AstraZeneca COVID-19 vaccine in Australia using a Bayesian network-modelling framework. Vaccine. 2021.
17. Immunisation Coalition. "CoRiCal: Covid Risk Calculator". 2021.
18. Fenton NE, S McLachlan, P Lucas, K Dube, GA Hitman, et al. "A Bayesian network model for personalised COVID19 risk assessment and contact tracing." medRxiv. 2021.
19. Australian Government Department of Health. Coronavirus (COVID-19) Case Numbers and Statistics. 2021.
20. Clift AK, Ruth H Keogh, Elizabeth Williamson, Andrew Hayward, Peter Horby. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: National derivation and validation cohort study. Br. Med. J. 2020: 371: m3731.
21. Boehmer TK, Kompaniyets L, Lavery AM, et al. Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data - United States, March 2020-January 2021. MMWR Morb Mortal Wkly Rep. 2021; 70: 1228-1232.
22. Hippisley-Cox J, Patone M, Mei XW, Saatci D, Dixon S, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: Self-controlled case series study. BMJ. 2021; 374: n1931.
23. MacIntyre CR, Veness B, Berger D, Hamad N, Bari N. Thrombosis with Thrombocytopenia Syndrome (TTS) following AstraZeneca ChAdOx1 nCoV-19 (AZD1222) COVID-19 vaccination - a risk-benefit analysis for people <60 years in Australia. Vaccine. 2021; 39: 4784-4787.
24. Cerebral Venous Sinus Thrombosis and Thrombotic Events After Vector-Based COVID-19 Vaccines, A Systematic Review and Meta-analysis, Neurology. 2021; 97: e2136-e2147.
25. Palaiodimou L, Maria-Ioanna Stefanou, Aristeidis H Katsanos, Diana Aguiar de Sousa, Jonathan M Coutinho, et al. Cerebral venous sinus thrombosis and thrombotic events after vector-based COVID-19 vaccines: A systematic review and meta-analysis. Neurology. 2021; 97: e2136-e2147.
26. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021; 384: 2092-2101.
27. Hippisley-Cox J, Xue W Mei, Kamlesh Khunti, Peter Watkinson, Manu Shankar-Hari, et al. Risk of thrombocytopenia and thromboembolism after covid-19 vaccination and SARS-CoV-2 positive testing: Self-controlled case series study. Br. Med. J. 2021; 374: n1931.
28. Scully M, Singh D, Lown R, Anthony Poles, Tom Solomon, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021; 384: 2202-2211.
29. Mehta PR, Mangion SA, Benger M, Biba R Stanton, Julia Czuprynska, et al. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination-a report of two UK cases. Brain Behav Immun. 2021; 95: 514-517.
30. Ostropolets A, Hripcsak G. COVID-19 vaccination effectiveness rates by week and sources of bias. medRxiv. 2021.
31. Shaker MS, Dana V Wallace, David BK Golden, John Oppenheimer, Jonathan A Bernstein, et al. "Anaphylaxis-a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis." Journal of Allergy and Clinical Immunology. 2020; 145: 1082-1123.
32. Cuker A. Management of the multiple phases of heparin-induced thrombocytopenia. Thromb Haemost. 2016; 116: 835-842.